Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials

Biometrics

Volumn 59, Issue 3, 2003, Pages 531-541

  Gilbert, Peter B ^a   Bosch, Ronald J ^b   Hudgens, Michael G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

Causal inference; Posttreatment selection bias; Principal stratification

Indexed keywords

DISEASES; LOAD TESTING; RANDOM PROCESSES; SENSITIVITY ANALYSIS;

CAUSAL INFERENCES; HIV INFECTION; HIV VIRAL LOADS; HIV/AIDS; POST TREATMENT; POSTTREATMENT SELECTION BIAS; PRINCIPAL STRATIFICATION; RANDOMISATION; SELECTION BIAS; VIRAL LOAD;

VACCINES;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

DISEASE TRANSMISSION; HUMAN IMMUNODEFICIENCY VIRUS; SENSITIVITY ANALYSIS; VACCINATION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIOASSAY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT SELECTION; PRINCIPAL COMPONENT ANALYSIS; RANDOMIZATION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL; VACCINATION; VIRUS LOAD; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0041833620     PISSN: 0006341X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1541-0420.00063     Document Type: Article

References (28)

1. Angrist, J., Imbens, G. W., and Rubin, D. B. (1996). Identification of causal effects using instrumental variables (with discussion). Journal of the American Statistical Association 91, 444-472.
2. Barouch, D. H., Kunstman, J., Kuroda, M. J., et al. (2002). Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339.
3. Burke, D. S. (1992). Human HIV vaccine trials: Does antibody-dependent enhancement pose a genuine risk? Perspectives in Biology and Medicine 35, 511-530.
4. Coombs, R. W., Speck, C. E., Hughes, J. P., et al. (1998). Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: Evidence for compartmentalization of HIV-1 between semen and blood. Journal of Infectious Diseases 177, 320-330.
5. D'Agostino, R. B. and Stephens, M. A. (1986). Goodness-of-fit techniques. New York: Marcel Dekker.
6. Francis, D. P., Gregory, T., McElrath, M. J., Belshe, R. B., Gorse, G. J., Migasena, S., Kitayaporn, D., Pitisuttitham, P., Matthews, T., Schwartz, D. H., and Berman, P. W. (1998). Advancing AIDSVAX to Phase III: Safety, immunogenicity, and plans for Phase III. AIDS Research and Human Retroviruses, 14(Suppl. 3), S325-S331.
7. Frangakis, C. E. and Rubin, D. B. (2002). Principal stratification in causal inference. Biometrics 58, 21-29.
8. Goetghebeur, E., Kenward, M., Molenberghs, G., and Vansteelandt, S. (2000). Inferential tools for sensitivity analysis and noncompliance in clinical trials. In Proceedings of the Annual Meeting. Indianapolis, Indiana: American Statistical Association.
9. Halloran, M. E. and Struchiner, C. J. (1995). Causal inference in infectious diseases. Epidemiology 6, 142-151.
10. Halloran, M. E., Haber, M. J., and Longini, I. M. (1992). Interpretation and estimation of vaccine efficacy under heterogeneity. American Journal of Epidemiology 136, 328-343.
11. Holland, P. (1986). Statistics and causal inference. Journal of the American Statistical Association 81, 945-961.
12. Hudgens, M. G., Hoering, A., and Self, S. G. (2003). On the analysis of viral load endpoints in HIV vaccine trials. Statistics in Medicine, in press.
13. Mascola, J. R., Mathieson, B. J., Zack, P. M., Walker, M. C., Halstead, S. B., and Burke, D. S. (1993). Summary report: Workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Research and Human Retroviruses 9, 1175-1184.
14. Mellors, J. W., Munoz, A., Giorgi, J. V., et al. (1997). Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 126, 946-954.
15. Nabel, G. J. (2001). Challenges and opportunities for development of an AIDS vaccine. Nature 410, 1002-1007.
16. Quinn, T. C., Wawer, M. J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., Meehan, M. O., Lutalo, T., and Gray, R. H. (2000). Viral load and heterosexual transmission of human immunodeficiency virus type 1. New England Journal of Medicine 342, 921-929.
17. Rida, W. N., Fast, P., Hoff, R., and Fleming, T. R. (1997). Intermediate-sized trials for the evaluation of HIV vaccine candidates: A workshop summary. Journal of Acquired Immune Deficiency Syndrome 16, 195-203.
18. Rida, W. N. and Lawrence, D. L. (1995). Prophylactic HIV vaccine trials. In AIDS Clinical Trials: Guidelines for Design and Analysis, D. M. Finkelstein, D. A. Schoenfeld (eds), 319-348. New York: Wiley-Liss.
19. Robins, J. M. and Greenland, S. (1992). Identifiability and exchangeability of direct and indirect effects. Epidemiology 3, 143-155.
20. Rosenbaum, P. R. (1984). The consequences of adjustment for a concomitant variable that has been affected by the treatment. Journal of the Royal Statistical Society, Series A 147, 656-666.
21. Rosenbaum, P. R. and Rubin, D. B. (1983). Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome. Journal of the Royal Statistical Society, Series B 45, 212-218.
22. Rotnitzky, A. and Robins, J. (1997). Analysis of semiparametric regression models with nonignorable nonresponse. Biometrics 16, 81-102.
23. Rubin, D. B. (1974). Estimating causal effects of treatments in randomized and nonrandomized studies. Journal of Educational Psychology 66, 688-701.
24. Rubin, D. B. (1978). Bayesian inference for causal effects. Annals of Statistics 6, 34-58.
25. Rubin, D. B. (2000). Comment on "Causal inference without counterfactuals," by A. P. Dawid. Journal of the American Statistical Association 95, 435-437.
26. Scharfstein, D. O., Rotnitzky, A., and Robins, J. M. (1999). Adjusting for nonignorable drop-out using semiparametric nonresponse models. Journal of the American Statistical Association 94, 1096-1146.
27. Shiver, J. W., Fu, T.-M., Chen, L., et al. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 415, 331-335.
28. Sterling, T. R., Vlahov, D., Astemborski, J., Hoover, D. R., Margolick, J. B., and Quinn, T. C. (2001). Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. New England Journal of Medicine 344, 720-725.